Literature DB >> 15864605

Can pathological complete response in the primary tumour following pre-operative pelvic chemoradiotherapy for T3-T4 rectal cancer predict for sterilisation of pelvic lymph nodes, a low risk of local recurrence and the appropriateness of local excision?

R Hughes1, R Glynne-Jones, J Grainger, P Richman, A Makris, M Harrison, R Ashford, R A Harrison, J I Livingstone, P J McDonald, J Meyrick Thomas, I C Mitchell, J M A Northover, R Phillips, M Wallace, A Windsor, J R Novell.   

Abstract

INTRODUCTION: Local excision is considered inappropriate treatment for T3-T4 rectal adenocarcinomas, as it cannot provide prognostic information regarding lymph node involvement and has a high risk of pelvic recurrence. Preoperative chemoradiation (CRT) studies in rectal cancer suggest that a pathological complete response (pCR) in the primary tumour provides an excellent long-term outcome. If downstaging to stage pT0 predicts a tumour response within the perirectal and pelvic lymph nodes, this may allow local excision to be performed without increased risk of pelvic recurrence. This retrospective study aimed to determine the incidence of involved lymph nodes following pCR (ypT0) after preoperative CRT and total mesorectal excision.
METHOD: The outcome and treatment details of 211 patients undergoing preoperative CRT for clinically staged T3-T4 unresectable rectal adenocarcinomas between 1993 and 2003 at Mount Vernon Hospital were reviewed.
RESULTS: Data were recorded from the 143 patients who completed treatment with a median follow-up of 25 months. Twenty-three patients (18%) were found to have had a pCR. Four out of 23 patients (17%) had involved lymph nodes. No pelvic recurrences developed after a ypCR. Overall survival was similar for patients with ypT0 or residual tumour.
CONCLUSION: Pathological complete response in the primary tumour failed to predict a response in the perirectal lymph nodes (p=0.08). The degree of response predicted a lymph node response (p=0.02). The detection of ypCR identified patients with a low rate of pelvic recurrence. This may in the future allow selection of patients for whom local excision can be performed without a higher risk of local relapse.

Entities:  

Mesh:

Year:  2005        PMID: 15864605     DOI: 10.1007/s00384-005-0749-y

Source DB:  PubMed          Journal:  Int J Colorectal Dis        ISSN: 0179-1958            Impact factor:   2.571


  26 in total

1.  Variables correlated with the risk of lymph node metastasis in early rectal cancer.

Authors:  J T Brodsky; G K Richard; A M Cohen; B D Minsky
Journal:  Cancer       Date:  1992-01-15       Impact factor: 6.860

Review 2.  Abdominoperineal resection for adenocarcinoma of the low rectum.

Authors:  D A Rothenberger; W D Wong
Journal:  World J Surg       Date:  1992 May-Jun       Impact factor: 3.352

3.  A pathologic complete response to preoperative chemoradiation is associated with lower local recurrence and improved survival in rectal cancer patients treated by mesorectal excision.

Authors:  Julio García-Aguilar; Enrique Hernandez de Anda; Prayuth Sirivongs; Suk-Hwan Lee; Robert D Madoff; David A Rothenberger
Journal:  Dis Colon Rectum       Date:  2003-03       Impact factor: 4.585

4.  Local excision of rectal carcinoma.

Authors:  M G Varma; S J Rogers; T R Schrock; M L Welton
Journal:  Arch Surg       Date:  1999-08

5.  Local excision of T2 and T3 rectal cancers after downstaging chemoradiation.

Authors:  C J Kim; T J Yeatman; D Coppola; A Trotti; B Williams; J S Barthel; W Dinwoodie; R C Karl; J Marcet
Journal:  Ann Surg       Date:  2001-09       Impact factor: 12.969

6.  Preoperative radiochemotherapy in rectal cancer: long-term results of a phase II trial.

Authors:  J F Bosset; V Magnin; P Maingon; G Mantion; E P Pelissier; M Mercier; G Chaillard; J C Horiot
Journal:  Int J Radiat Oncol Biol Phys       Date:  2000-01-15       Impact factor: 7.038

7.  Long-term follow-up of patients with rectal cancer managed by local excision with and without adjuvant irradiation.

Authors:  A Chakravarti; C C Compton; P C Shellito; W C Wood; J Landry; S R Machuta; D Kaufman; M Ancukiewicz; C G Willett
Journal:  Ann Surg       Date:  1999-07       Impact factor: 12.969

8.  All patients with small intramural rectal cancers are at risk for lymph node metastasis.

Authors:  D Blumberg; P B Paty; J G Guillem; A I Picon; B D Minsky; W D Wong; A M Cohen
Journal:  Dis Colon Rectum       Date:  1999-07       Impact factor: 4.585

9.  Determination of the optimal dose of 5-fluorouracil when combined with low dose D,L-leucovorin and irradiation in rectal cancer: results of three consecutive phase II studies. EORTC Radiotherapy Group.

Authors:  J F Bosset; J J Pavy; H P Hamers; J C Horiot; M C Fabri; P Rougier; F Eschwege; S Schraub
Journal:  Eur J Cancer       Date:  1993       Impact factor: 9.162

10.  Predicting the node-negative mesorectum after preoperative chemoradiation for locally advanced rectal carcinoma.

Authors:  Isabelle Bedrosian; Miguel A Rodriguez-Bigas; Barry Feig; Kelly K Hunt; Lee Ellis; Steven A Curley; Jean Nicolas Vauthey; Marc Delclos; Christopher Crane; Nora Janjan; John M Skibber
Journal:  J Gastrointest Surg       Date:  2004-01       Impact factor: 3.452

View more
  42 in total

Review 1.  Oncological outcomes of local excision compared with radical surgery after neoadjuvant chemoradiotherapy for rectal cancer: a systematic review and meta-analysis.

Authors:  Irshad Shaikh; Alan Askari; Suzana Ourû; Janindra Warusavitarne; Thanos Athanasiou; Omar Faiz
Journal:  Int J Colorectal Dis       Date:  2014-11-04       Impact factor: 2.571

2.  Can adequate lymphadenectomy be obtained by laparoscopic resection in rectal cancer? Results of a case-control study in 200 patients.

Authors:  Samer Sara; Gilles Poncet; David Voirin; Marie-Hélène Laverriere; Daniel Anglade; Jean-Luc Faucheron
Journal:  J Gastrointest Surg       Date:  2010-05-26       Impact factor: 3.452

3.  Apparent diffusion coefficient for evaluating tumour response to neoadjuvant chemoradiation therapy for locally advanced rectal cancer.

Authors:  Seung Ho Kim; Jae Young Lee; Jeong Min Lee; Joon Koo Han; Byung Ihn Choi
Journal:  Eur Radiol       Date:  2010-10-27       Impact factor: 5.315

4.  Locally advanced rectal cancer: is diffusion weighted MRI helpful for the identification of complete responders (ypT0N0) after neoadjuvant chemoradiation therapy?

Authors:  S Sassen; M de Booij; M Sosef; R Berendsen; G Lammering; R Clarijs; M Bakker; R Beets-Tan; F Warmerdam; R Vliegen
Journal:  Eur Radiol       Date:  2013-07-06       Impact factor: 5.315

5.  Prognostic significance of tumor regression in lymph nodes after neoadjuvant therapy for rectal carcinoma.

Authors:  M J Fernández-Aceñero; M Granja; J Sastre; B García-Paredes; L Estrada
Journal:  Virchows Arch       Date:  2016-01-11       Impact factor: 4.064

Review 6.  Paradigm-shifting new evidence for treatment of rectal cancer.

Authors:  Alessandro Fichera; Marco E Allaix
Journal:  J Gastrointest Surg       Date:  2013-07-26       Impact factor: 3.452

7.  The risk of nodal disease in patients with pathological complete responses after neoadjuvant chemoradiation for rectal cancer: a systematic review, meta-analysis, and meta-regression.

Authors:  Ian Jun Yan Wee; Hai Man Cao; James Chi-Yong Ngu
Journal:  Int J Colorectal Dis       Date:  2019-07-04       Impact factor: 2.571

Review 8.  Risk factors for local recurrence following neoadjuvant chemoradiotherapy for rectal cancers.

Authors:  Jia-Yuan Peng; Zhong-Nan Li; Yu Wang
Journal:  World J Gastroenterol       Date:  2013-08-28       Impact factor: 5.742

Review 9.  Treatment of locally advanced rectal cancer: controversies and questions.

Authors:  Atthaphorn Trakarnsanga; Suthinee Ithimakin; Martin R Weiser
Journal:  World J Gastroenterol       Date:  2012-10-21       Impact factor: 5.742

10.  Distribution of residual cancer cells in the bowel wall after neoadjuvant chemoradiation in patients with rectal cancer.

Authors:  Marjun P Duldulao; Wendy Lee; Leanne Streja; Peiguo Chu; Wenyan Li; Zhenbin Chen; Joseph Kim; Julio Garcia-Aguilar
Journal:  Dis Colon Rectum       Date:  2013-02       Impact factor: 4.585

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.